The Ministry of AYUSH has developed and launched the AYUSH Sanjivani mobile application to generate data on the acceptance and usage of Ayush advocacies and measures among the population and its impact in the prevention of COVID-19.
The Pharmacy Act 1948 was enacted on 4.3.48 with the following preamble- "An Act to regulate the profession of pharmacy. Whereas it is expedient to make better provision for the regulation of the profession and practice of pharmacy and for that purpose to constitute Pharmacy Councils".
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad. Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
On 2 September 2020, WHO issued an interim guideline on the use of dexamethasone and other corticosteroids for the treatment of COVID-19. The guidelines were developed by a panel of WHO and international experts and investigators and is based on evidence collected from seven clinical trials.
What is the difference between Influenza (Flu) and COVID-19? Influenza (Flu) and COVID-19 are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 is caused by infection with a new coronavirus (called SARS-CoV-2), and flu is caused…
An influenza pandemic is a global outbreak of a new influenza A virus. Pandemics happen when new (novel) influenza A viruses emerge which are able to infect people easily and spread from person to person in an efficient and sustained way. In the spring of 2009, a novel influenza A (H1N1) virus emerged. It was detected first in the United States and spread quickly across the United States and the world. This new H1N1 virus contained a unique combination of influenza genes not previously identified in animals or people. It should be noted that influenza virus testing is not required to make a clinical diagnosis of influenza in outpatients with suspected influenza, particularly during increased influenza activity when seasonal influenza A and B viruses are circulating in the local community.
SARS-CoV-2 already has a different mutation in circulation and several others have been predicted based on evolutionary benefits (Korber et al., 2020; Padhi and Tripathi, 2020). The kind of epidemiological demands that might arise in case a community transmission of a milder viral strain is swiftly followed by the appearance of a virulent one can be quite challenging.
We have designed this study to evaluate COVID-19 vaccine effectiveness by antibody testing and evaluate vaccine hesitancy rate, among the healthcare workers of Max Group of Hospitals. We would do antibody testing at day 0 (vaccination day or pre-vaccination) followed by 7, 14, 28, 45, 90th day of vaccination. This study would involve a brief questionnaire asking about the health status of the participants related to COVID-19 and side-effects post-vaccination.
The WHO Emergency Use Listing Procedure (EUL) is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of these products to people affected by a public health emergency. This will assist interested UN procurement agencies and Member States in determining the acceptability of using specific products, based on an essential set of available quality, safety, and efficacy and performance data.
The international team recognized the impact of the epidemic on Wuhan, from affected individuals and communities to government officials, scientists and health workers. The team commended the engagement of all the professionals who had spent long hours analysing very large quantities of data to support its work. In conclusion, the team called for a continued scientific and collaborative approach to be taken towards tracing the origins of COVID-19.
Directorate of Drugs Control under The Department of Health & Family Welfare (DoHFW), Government of West Bengal is responsible for effective implementation of Drugs and Cosmetics Act, 1940 and rules formed thereunder, Drug Price Control Order, 2013, Narcotic Drugs and Psychotropic Substances Act, 1985, Drugs and Magic Remedies (Objectionable Advertisement) act, 1954.